In the landmark PARACCT trial, allogeneic MSC administration in MI patients reduced infarct scar size by 33% and improved left ventricular ejection fraction, outcomes attributed in part to VEGF-driven angiogenesis (Natsumeda et al., 2017; Williams et al., 2013). Here, VEGFA is linked to myocardial infarction.